FDA rejects Capricor Duchenne therapy, a decision that was a long time coming
AI Image

FDA rejects Capricor Duchenne therapy, a decision that was a long time coming

STAT • • business

Key Points:

  • The FDA has rejected deramiocel, a cell therapy developed by Capricor Therapeutics for Duchenne muscular dystrophy patients.
  • The treatment targeted teenagers and young men with Duchenne who had lost the ability to walk and currently have limited treatment options.
  • Two randomized clinical trials conducted by Capricor failed to demonstrate that deramiocel could prevent heart failure or preserve muscle function.
  • The decision highlights the complexities involved in regulating drugs for Duchenne, a progressive muscle-wasting disease.

Trending Business

Trending Technology

Trending Health